Category: BT600

Biora Therapeutics has reported significant advancements in its BT-600 program and BioJet platform during its recent earnings call. The company announced successful Phase I clinical trial results for its BT-600 program, utilizing the NaviCap platform for targeted drug delivery to the colon. This approach demonstrated a lower systemic drug level…